nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—Labetalol—Formoterol—chronic obstructive pulmonary disease	0.196	0.5	CrCrCtD
Tolterodine—Labetalol—Arformoterol—chronic obstructive pulmonary disease	0.196	0.5	CrCrCtD
Tolterodine—CHRM5—Tiotropium—chronic obstructive pulmonary disease	0.092	0.191	CbGbCtD
Tolterodine—CHRM3—Tiotropium—chronic obstructive pulmonary disease	0.0588	0.122	CbGbCtD
Tolterodine—CHRM1—Tiotropium—chronic obstructive pulmonary disease	0.0512	0.106	CbGbCtD
Tolterodine—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.0472	0.0978	CbGbCtD
Tolterodine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0254	0.0526	CbGbCtD
Tolterodine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0254	0.0526	CbGbCtD
Tolterodine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0211	0.0438	CbGbCtD
Tolterodine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0211	0.0438	CbGbCtD
Tolterodine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0193	0.04	CbGbCtD
Tolterodine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0193	0.04	CbGbCtD
Tolterodine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0172	0.0357	CbGbCtD
Tolterodine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0162	0.0336	CbGbCtD
Tolterodine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.016	0.0332	CbGbCtD
Tolterodine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0109	0.0227	CbGbCtD
Tolterodine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0107	0.0221	CbGbCtD
Tolterodine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0104	0.0216	CbGbCtD
Tolterodine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0093	0.0193	CbGbCtD
Tolterodine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00546	0.0113	CbGbCtD
Tolterodine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00515	0.0107	CbGbCtD
Tolterodine—Gastrooesophageal reflux disease—Roflumilast—chronic obstructive pulmonary disease	0.0021	0.0226	CcSEcCtD
Tolterodine—Influenza-like symptoms—Tiotropium—chronic obstructive pulmonary disease	0.00167	0.018	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Aminophylline—chronic obstructive pulmonary disease	0.0014	0.0151	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Tiotropium—chronic obstructive pulmonary disease	0.00132	0.0142	CcSEcCtD
Tolterodine—Memory impairment—Montelukast—chronic obstructive pulmonary disease	0.0012	0.013	CcSEcCtD
Tolterodine—Influenza like illness—Tiotropium—chronic obstructive pulmonary disease	0.00116	0.0125	CcSEcCtD
Tolterodine—Urinary tract infection—Roflumilast—chronic obstructive pulmonary disease	0.00103	0.0111	CcSEcCtD
Tolterodine—Disorientation—Aminophylline—chronic obstructive pulmonary disease	0.00103	0.0111	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.0109	CcSEcCtD
Tolterodine—Sinusitis—Roflumilast—chronic obstructive pulmonary disease	0.000996	0.0107	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Aminophylline—chronic obstructive pulmonary disease	0.000949	0.0102	CcSEcCtD
Tolterodine—Dementia—Prednisone—chronic obstructive pulmonary disease	0.000924	0.00996	CcSEcCtD
Tolterodine—Urinary retention—Aminophylline—chronic obstructive pulmonary disease	0.000874	0.00942	CcSEcCtD
Tolterodine—Abnormal vision—Arformoterol—chronic obstructive pulmonary disease	0.00084	0.00905	CcSEcCtD
Tolterodine—Abnormal vision—Formoterol—chronic obstructive pulmonary disease	0.00084	0.00905	CcSEcCtD
Tolterodine—Urinary retention—Tiotropium—chronic obstructive pulmonary disease	0.000824	0.00888	CcSEcCtD
Tolterodine—Dry skin—Tiotropium—chronic obstructive pulmonary disease	0.000794	0.00856	CcSEcCtD
Tolterodine—Disorientation—Montelukast—chronic obstructive pulmonary disease	0.000766	0.00825	CcSEcCtD
Tolterodine—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.000758	0.00817	CcSEcCtD
Tolterodine—Vertigo—Roflumilast—chronic obstructive pulmonary disease	0.000745	0.00803	CcSEcCtD
Tolterodine—Palpitations—Roflumilast—chronic obstructive pulmonary disease	0.000733	0.0079	CcSEcCtD
Tolterodine—Anxiety—Roflumilast—chronic obstructive pulmonary disease	0.000704	0.00759	CcSEcCtD
Tolterodine—Dysuria—Tiotropium—chronic obstructive pulmonary disease	0.0007	0.00755	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000696	0.0075	CcSEcCtD
Tolterodine—Infection—Roflumilast—chronic obstructive pulmonary disease	0.000673	0.00725	CcSEcCtD
Tolterodine—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000649	0.00699	CcSEcCtD
Tolterodine—Dry skin—Arformoterol—chronic obstructive pulmonary disease	0.000641	0.00691	CcSEcCtD
Tolterodine—Dry skin—Formoterol—chronic obstructive pulmonary disease	0.000641	0.00691	CcSEcCtD
Tolterodine—Sinusitis—Tiotropium—chronic obstructive pulmonary disease	0.000626	0.00675	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000617	0.00665	CcSEcCtD
Tolterodine—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.000596	0.00642	CcSEcCtD
Tolterodine—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.00059	0.00636	CcSEcCtD
Tolterodine—Flushing—Aminophylline—chronic obstructive pulmonary disease	0.00059	0.00636	CcSEcCtD
Tolterodine—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000584	0.00629	CcSEcCtD
Tolterodine—Bronchitis—Arformoterol—chronic obstructive pulmonary disease	0.000581	0.00626	CcSEcCtD
Tolterodine—Bronchitis—Formoterol—chronic obstructive pulmonary disease	0.000581	0.00626	CcSEcCtD
Tolterodine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000579	0.00624	CcSEcCtD
Tolterodine—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.000578	0.00623	CcSEcCtD
Tolterodine—Bronchitis—Montelukast—chronic obstructive pulmonary disease	0.000569	0.00614	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000562	0.00605	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Formoterol—chronic obstructive pulmonary disease	0.000562	0.00605	CcSEcCtD
Tolterodine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.000558	0.00601	CcSEcCtD
Tolterodine—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.000554	0.00597	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Montelukast—chronic obstructive pulmonary disease	0.00055	0.00593	CcSEcCtD
Tolterodine—Bronchitis—Salbutamol—chronic obstructive pulmonary disease	0.000549	0.00591	CcSEcCtD
Tolterodine—Delusion—Prednisone—chronic obstructive pulmonary disease	0.000536	0.00577	CcSEcCtD
Tolterodine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000535	0.00577	CcSEcCtD
Tolterodine—Dysuria—Salbutamol—chronic obstructive pulmonary disease	0.000534	0.00575	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00053	0.00572	CcSEcCtD
Tolterodine—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000524	0.00564	CcSEcCtD
Tolterodine—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000524	0.00564	CcSEcCtD
Tolterodine—Sinusitis—Formoterol—chronic obstructive pulmonary disease	0.000505	0.00545	CcSEcCtD
Tolterodine—Sinusitis—Arformoterol—chronic obstructive pulmonary disease	0.000505	0.00545	CcSEcCtD
Tolterodine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000499	0.00538	CcSEcCtD
Tolterodine—Labetalol—ADRB2—chronic obstructive pulmonary disease	0.000496	0.345	CrCbGaD
Tolterodine—Sinusitis—Montelukast—chronic obstructive pulmonary disease	0.000495	0.00534	CcSEcCtD
Tolterodine—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000495	0.00533	CcSEcCtD
Tolterodine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.000489	0.00527	CcSEcCtD
Tolterodine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000486	0.00524	CcSEcCtD
Tolterodine—Memory impairment—Prednisone—chronic obstructive pulmonary disease	0.000483	0.00521	CcSEcCtD
Tolterodine—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.000477	0.00514	CcSEcCtD
Tolterodine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000477	0.00514	CcSEcCtD
Tolterodine—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000476	0.00514	CcSEcCtD
Tolterodine—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000476	0.00514	CcSEcCtD
Tolterodine—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000471	0.00508	CcSEcCtD
Tolterodine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000469	0.00506	CcSEcCtD
Tolterodine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.000466	0.00502	CcSEcCtD
Tolterodine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.000466	0.00502	CcSEcCtD
Tolterodine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000463	0.00499	CcSEcCtD
Tolterodine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000461	0.00497	CcSEcCtD
Tolterodine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000452	0.00487	CcSEcCtD
Tolterodine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000449	0.00483	CcSEcCtD
Tolterodine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000448	0.00483	CcSEcCtD
Tolterodine—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000444	0.00479	CcSEcCtD
Tolterodine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000444	0.00479	CcSEcCtD
Tolterodine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000441	0.00475	CcSEcCtD
Tolterodine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000434	0.00468	CcSEcCtD
Tolterodine—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000426	0.00459	CcSEcCtD
Tolterodine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000424	0.00457	CcSEcCtD
Tolterodine—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000424	0.00457	CcSEcCtD
Tolterodine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000423	0.00456	CcSEcCtD
Tolterodine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000416	0.00448	CcSEcCtD
Tolterodine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000397	0.00428	CcSEcCtD
Tolterodine—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000392	0.00422	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000391	0.00422	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000388	0.00418	CcSEcCtD
Tolterodine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000385	0.00415	CcSEcCtD
Tolterodine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.00415	CcSEcCtD
Tolterodine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000377	0.00406	CcSEcCtD
Tolterodine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000375	0.00404	CcSEcCtD
Tolterodine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00401	CcSEcCtD
Tolterodine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00401	CcSEcCtD
Tolterodine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000369	0.00398	CcSEcCtD
Tolterodine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000364	0.00393	CcSEcCtD
Tolterodine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000364	0.00392	CcSEcCtD
Tolterodine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000363	0.00392	CcSEcCtD
Tolterodine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00386	CcSEcCtD
Tolterodine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00386	CcSEcCtD
Tolterodine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00386	CcSEcCtD
Tolterodine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00386	CcSEcCtD
Tolterodine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000357	0.00385	CcSEcCtD
Tolterodine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000357	0.00385	CcSEcCtD
Tolterodine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000357	0.00385	CcSEcCtD
Tolterodine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000357	0.00385	CcSEcCtD
Tolterodine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00379	CcSEcCtD
Tolterodine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000351	0.00378	CcSEcCtD
Tolterodine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000351	0.00378	CcSEcCtD
Tolterodine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000351	0.00378	CcSEcCtD
Tolterodine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00035	0.00377	CcSEcCtD
Tolterodine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000348	0.00375	CcSEcCtD
Tolterodine—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000347	0.00374	CcSEcCtD
Tolterodine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000344	0.0037	CcSEcCtD
Tolterodine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000344	0.0037	CcSEcCtD
Tolterodine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000344	0.0037	CcSEcCtD
Tolterodine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000344	0.0037	CcSEcCtD
Tolterodine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000341	0.00368	CcSEcCtD
Tolterodine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000341	0.00368	CcSEcCtD
Tolterodine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00365	CcSEcCtD
Tolterodine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00365	CcSEcCtD
Tolterodine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.00364	CcSEcCtD
Tolterodine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000337	0.00363	CcSEcCtD
Tolterodine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00363	CcSEcCtD
Tolterodine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00363	CcSEcCtD
Tolterodine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000335	0.00361	CcSEcCtD
Tolterodine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000335	0.00361	CcSEcCtD
Tolterodine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000334	0.0036	CcSEcCtD
Tolterodine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000333	0.00359	CcSEcCtD
Tolterodine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.00357	CcSEcCtD
Tolterodine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000324	0.0035	CcSEcCtD
Tolterodine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000324	0.0035	CcSEcCtD
Tolterodine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000322	0.00347	CcSEcCtD
Tolterodine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000317	0.00341	CcSEcCtD
Tolterodine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000314	0.00338	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000313	0.00337	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000313	0.00337	CcSEcCtD
Tolterodine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000309	0.00333	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000307	0.00331	CcSEcCtD
Tolterodine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00329	CcSEcCtD
Tolterodine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00329	CcSEcCtD
Tolterodine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000302	0.00326	CcSEcCtD
Tolterodine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000302	0.00326	CcSEcCtD
Tolterodine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00323	CcSEcCtD
Tolterodine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000299	0.00322	CcSEcCtD
Tolterodine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000298	0.00321	CcSEcCtD
Tolterodine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000296	0.00319	CcSEcCtD
Tolterodine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000296	0.00319	CcSEcCtD
Tolterodine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.00319	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000296	0.00319	CcSEcCtD
Tolterodine—Chlorphenamine—SLC6A4—chronic obstructive pulmonary disease	0.000295	0.205	CrCbGaD
Tolterodine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00317	CcSEcCtD
Tolterodine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00317	CcSEcCtD
Tolterodine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00317	CcSEcCtD
Tolterodine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00317	CcSEcCtD
Tolterodine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00029	0.00313	CcSEcCtD
Tolterodine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00311	CcSEcCtD
Tolterodine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000288	0.0031	CcSEcCtD
Tolterodine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00308	CcSEcCtD
Tolterodine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000283	0.00305	CcSEcCtD
Tolterodine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000283	0.00305	CcSEcCtD
Tolterodine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000283	0.00305	CcSEcCtD
Tolterodine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000282	0.00303	CcSEcCtD
Tolterodine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00303	CcSEcCtD
Tolterodine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00303	CcSEcCtD
Tolterodine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.00302	CcSEcCtD
Tolterodine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00299	CcSEcCtD
Tolterodine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00299	CcSEcCtD
Tolterodine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00297	CcSEcCtD
Tolterodine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00293	CcSEcCtD
Tolterodine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00293	CcSEcCtD
Tolterodine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00288	CcSEcCtD
Tolterodine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.00288	CcSEcCtD
Tolterodine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00287	CcSEcCtD
Tolterodine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00286	CcSEcCtD
Tolterodine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00276	CcSEcCtD
Tolterodine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00273	CcSEcCtD
Tolterodine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00273	CcSEcCtD
Tolterodine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000252	0.00272	CcSEcCtD
Tolterodine—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000252	0.00272	CcSEcCtD
Tolterodine—Atomoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000248	0.172	CrCbGaD
Tolterodine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000248	0.00267	CcSEcCtD
Tolterodine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00266	CcSEcCtD
Tolterodine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00266	CcSEcCtD
Tolterodine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000241	0.0026	CcSEcCtD
Tolterodine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00258	CcSEcCtD
Tolterodine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00253	CcSEcCtD
Tolterodine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00253	CcSEcCtD
Tolterodine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00251	CcSEcCtD
Tolterodine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00248	CcSEcCtD
Tolterodine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00245	CcSEcCtD
Tolterodine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00245	CcSEcCtD
Tolterodine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000223	0.0024	CcSEcCtD
Tolterodine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00239	CcSEcCtD
Tolterodine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00233	CcSEcCtD
Tolterodine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00232	CcSEcCtD
Tolterodine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00232	CcSEcCtD
Tolterodine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00231	CcSEcCtD
Tolterodine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00227	CcSEcCtD
Tolterodine—Phenprocoumon—ALB—chronic obstructive pulmonary disease	0.000209	0.145	CrCbGaD
Tolterodine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.00225	CcSEcCtD
Tolterodine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000205	0.00221	CcSEcCtD
Tolterodine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00219	CcSEcCtD
Tolterodine—Atomoxetine—HTR2A—chronic obstructive pulmonary disease	0.000191	0.133	CrCbGaD
Tolterodine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000189	0.00204	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.00201	CcSEcCtD
Tolterodine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.00201	CcSEcCtD
Tolterodine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.00196	CcSEcCtD
Tolterodine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000177	0.0019	CcSEcCtD
Tolterodine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00172	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000153	0.00165	CcSEcCtD
Tolterodine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00163	CcSEcCtD
Tolterodine—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000149	0.0016	CcSEcCtD
Tolterodine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00152	CcSEcCtD
Tolterodine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00152	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.00148	CcSEcCtD
Tolterodine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000135	0.00146	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000135	0.00146	CcSEcCtD
Tolterodine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00145	CcSEcCtD
Tolterodine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000132	0.00142	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000123	0.00133	CcSEcCtD
Tolterodine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.00133	CcSEcCtD
Tolterodine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00128	CcSEcCtD
Tolterodine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00126	CcSEcCtD
Tolterodine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00126	CcSEcCtD
Tolterodine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000116	0.00125	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000111	0.0012	CcSEcCtD
Tolterodine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000111	0.00119	CcSEcCtD
Tolterodine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00115	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	9.96e-05	0.00107	CcSEcCtD
Tolterodine—Asthenia—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.00105	CcSEcCtD
Tolterodine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	9.25e-05	0.000997	CcSEcCtD
Tolterodine—Dizziness—Prednisone—chronic obstructive pulmonary disease	8.94e-05	0.000964	CcSEcCtD
Tolterodine—Headache—Prednisone—chronic obstructive pulmonary disease	8.47e-05	0.000913	CcSEcCtD
Tolterodine—CHRM2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	2.58e-05	0.000795	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.5e-05	0.000769	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.49e-05	0.000767	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.49e-05	0.000767	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.47e-05	0.000761	CbGpPWpGaD
Tolterodine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	2.46e-05	0.000757	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.45e-05	0.000755	CbGpPWpGaD
Tolterodine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	2.45e-05	0.000754	CbGpPWpGaD
Tolterodine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	2.43e-05	0.000747	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.4e-05	0.000737	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.39e-05	0.000735	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.36e-05	0.000728	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.35e-05	0.000723	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.33e-05	0.000716	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.32e-05	0.000713	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.31e-05	0.000711	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	2.31e-05	0.00071	CbGpPWpGaD
Tolterodine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.29e-05	0.000706	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.29e-05	0.000705	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.29e-05	0.000704	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.28e-05	0.000702	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.26e-05	0.000695	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.23e-05	0.000686	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	2.23e-05	0.000686	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.19e-05	0.000675	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.14e-05	0.000658	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.13e-05	0.000657	CbGpPWpGaD
Tolterodine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.11e-05	0.000649	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.1e-05	0.000646	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.1e-05	0.000646	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.1e-05	0.000646	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.03e-05	0.000623	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.01e-05	0.000619	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.01e-05	0.000618	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2e-05	0.000616	CbGpPWpGaD
Tolterodine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000615	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.99e-05	0.000613	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.93e-05	0.000595	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.92e-05	0.00059	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.91e-05	0.000587	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.86e-05	0.000572	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.85e-05	0.00057	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.84e-05	0.000565	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.83e-05	0.000564	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.83e-05	0.000564	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.83e-05	0.000562	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	1.8e-05	0.000553	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.8e-05	0.000553	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.78e-05	0.000548	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.76e-05	0.000542	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.76e-05	0.00054	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.75e-05	0.000539	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.75e-05	0.000537	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.74e-05	0.000536	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.73e-05	0.000533	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.67e-05	0.000514	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.65e-05	0.000509	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.65e-05	0.000508	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.65e-05	0.000508	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.64e-05	0.000504	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.63e-05	0.000503	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.63e-05	0.000502	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	1.62e-05	0.0005	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.62e-05	0.0005	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.62e-05	0.0005	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.61e-05	0.000494	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.59e-05	0.00049	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.53e-05	0.000472	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.5e-05	0.000462	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.5e-05	0.000461	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.49e-05	0.00046	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.49e-05	0.000458	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.48e-05	0.000457	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.48e-05	0.000456	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.48e-05	0.000455	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.47e-05	0.000454	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.47e-05	0.000452	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.47e-05	0.000452	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.46e-05	0.000449	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GCLC—chronic obstructive pulmonary disease	1.45e-05	0.000446	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.43e-05	0.000439	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.42e-05	0.000436	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.000435	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.41e-05	0.000434	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.000434	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.41e-05	0.000434	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.4e-05	0.000432	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.4e-05	0.00043	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.4e-05	0.00043	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.37e-05	0.00042	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.34e-05	0.000413	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.34e-05	0.000412	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.33e-05	0.000408	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CTGF—chronic obstructive pulmonary disease	1.32e-05	0.000407	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.32e-05	0.000405	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.29e-05	0.000398	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.29e-05	0.000398	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.29e-05	0.000397	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.28e-05	0.000393	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.26e-05	0.000388	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.22e-05	0.000375	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.19e-05	0.000365	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.18e-05	0.000363	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.18e-05	0.000362	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.17e-05	0.000362	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.17e-05	0.00036	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.16e-05	0.000357	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.14e-05	0.000349	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.13e-05	0.000347	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.08e-05	0.000332	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.08e-05	0.000331	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.07e-05	0.000329	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.05e-05	0.000323	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.03e-05	0.000318	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.03e-05	0.000317	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.03e-05	0.000317	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.03e-05	0.000317	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.02e-05	0.000315	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.02e-05	0.000314	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.02e-05	0.000313	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—HMOX1—chronic obstructive pulmonary disease	1e-05	0.000309	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.86e-06	0.000303	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.76e-06	0.0003	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.62e-06	0.000296	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.59e-06	0.000295	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.57e-06	0.000294	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.54e-06	0.000294	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.5e-06	0.000292	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	9.43e-06	0.00029	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.35e-06	0.000288	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.16e-06	0.000282	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.88e-06	0.000273	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.86e-06	0.000273	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.85e-06	0.000272	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.79e-06	0.000271	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.78e-06	0.00027	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.76e-06	0.00027	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.7e-06	0.000268	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	8.67e-06	0.000267	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	8.61e-06	0.000265	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	8.6e-06	0.000265	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.02e-06	0.000247	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.99e-06	0.000246	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.97e-06	0.000245	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.93e-06	0.000244	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.93e-06	0.000244	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	7.92e-06	0.000244	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.91e-06	0.000243	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.89e-06	0.000243	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.87e-06	0.000242	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	7.85e-06	0.000242	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.83e-06	0.000241	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.53e-06	0.000232	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.51e-06	0.000231	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.29e-06	0.000224	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.26e-06	0.000223	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.24e-06	0.000223	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.23e-06	0.000223	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.21e-06	0.000222	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.19e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.19e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.17e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.16e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.12e-06	0.000219	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.94e-06	0.000214	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.92e-06	0.000213	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.87e-06	0.000211	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.85e-06	0.000211	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.61e-06	0.000204	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.52e-06	0.000201	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.45e-06	0.000199	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.43e-06	0.000198	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.37e-06	0.000196	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.36e-06	0.000196	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.09e-06	0.000187	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.08e-06	0.000187	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.08e-06	0.000187	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.05e-06	0.000186	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.03e-06	0.000186	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ALB—chronic obstructive pulmonary disease	6.02e-06	0.000185	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	6e-06	0.000185	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.95e-06	0.000183	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.79e-06	0.000178	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NOS3—chronic obstructive pulmonary disease	5.76e-06	0.000177	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.76e-06	0.000177	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.75e-06	0.000177	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.74e-06	0.000177	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.67e-06	0.000175	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.59e-06	0.000172	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.54e-06	0.000171	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.51e-06	0.00017	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.31e-06	0.000163	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.3e-06	0.000163	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.29e-06	0.000163	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.25e-06	0.000162	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.24e-06	0.000161	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.18e-06	0.000159	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.16e-06	0.000159	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.06e-06	0.000156	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.05e-06	0.000155	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5e-06	0.000154	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.95e-06	0.000152	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.83e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.82e-06	0.000148	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.77e-06	0.000147	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.77e-06	0.000147	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.74e-06	0.000146	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.65e-06	0.000143	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.54e-06	0.00014	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.45e-06	0.000137	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.29e-06	0.000132	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.27e-06	0.000132	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.23e-06	0.00013	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.08e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.06e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.02e-06	0.000124	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.98e-06	0.000122	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.92e-06	0.000121	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.92e-06	0.000121	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.9e-06	0.00012	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.88e-06	0.000119	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.87e-06	0.000119	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.83e-06	0.000118	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.75e-06	0.000115	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.74e-06	0.000115	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.65e-06	0.000112	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.6e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.57e-06	0.00011	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.57e-06	0.00011	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.48e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.47e-06	0.000107	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.46e-06	0.000107	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.45e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.44e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.42e-06	0.000105	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.42e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.2e-06	9.84e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.19e-06	9.81e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.16e-06	9.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.13e-06	9.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.12e-06	9.61e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.09e-06	9.52e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.63e-06	8.1e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.62e-06	8.07e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.6e-06	7.99e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.41e-06	7.41e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.4e-06	7.39e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.38e-06	7.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.36e-06	7.25e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.25e-06	6.93e-05	CbGpPWpGaD
